UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 15, 2026

MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	0-26642	87-0494517
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

322 North 2200 West
Salt Lake City, Utah 84116
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	MYGN	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On September 16, 2026, Myriad Genetics, Inc. (the “Company”) announced that, effective September 16, 2026, Brian Donnelly no longer serves as Chief Commercial Officer of the Company. Mr. Donnelly is expected to remain as a non-executive employee of the Company through September 21, 2026 to assist in the transition of his responsibilities.

On September 15, 2026, the Company’s Board of Directors (the “Board”) appointed Vishal Sikri, currently serving as the Company’s Senior Vice President, Product, as the Company’s Executive Vice President, Commercial, effective September 16, 2026. Mr. Sikri’s appointment as Executive Vice President, Commercial, was announced by the Company via press release on September 16, 2026.

ITEM 7.01 Regulation FD Disclosure

A copy of the press release announcing Mr. Donnelly’s departure and Mr. Sikri’s appointment as Executive Vice President, Commercial, is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

ITEM 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press Release dated September 16, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

Limitation on Incorporation by Reference. In accordance with General Instruction B.2 of Form 8-K, the information set forth in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYRIAD GENETICS, INC.

Date: September 16, 2026

By: /s/ Benjamin R. Wheeler
Benjamin R. Wheeler
Chief Financial Officer

Exhibit 99.1

Myriad genetics

NEWS RELEASE

Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial

SALT LAKE CITY, September 16, 2026 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been promoted to Executive Vice President - Commercial, effective September 16, 2026.

Vishal has served as the SVP of Product at Myriad for the past year. He has deep understanding of molecular diagnostics and oncology as well as extensive business and commercial leadership experience from his prior roles at other notable companies.

Brian Donnelly, who has served as Chief Commercial Officer since May of 2025, will be departing Myriad on September 21, 2026.

“I want to thank Brian for his contributions to Myriad,” said Sam Raha, President and CEO of Myriad Genetics. “We are excited to have Vishal lead our commercial organization. His deep domain knowledge along with strong track record of driving growth and operational excellence will be instrumental in enabling the execution of our cancer care continuum focus and profitable growth strategy going forward.”

“I’m energized to lead the commercial organization at this important stage for Myriad,” said Mr. Sikri. “I look forward to partnering with Sam and the executive leadership team to advance Myriad’s mission, serve more patients and healthcare providers, and create increased value for shareholders.”

The company is reaffirming its financial guidance for the full-year 2026, as announced during its second quarter 2026 earnings call on July 30, 2026.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company is reaffirming its financial guidance for the full-year 2026, as announced during its second quarter 2026 earnings call, and Mr. Sikri's deep domain knowledge along with strong track record of driving growth and operational excellence will be instrumental in enabling the execution of the company's Cancer Care Continuum focus and profitable growth strategy going forward. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact
Andria Rosell
(385) 202-3510
PR@myriad.com